Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

Recruiting now · Phase 3

Conditions studied: Bowel; Stricture

In brief

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Key facts

Study ID

NCT05561127

Run by

GIE Medical

People needed

171

Starts

2023-11-01

Expected to finish

2032-06-01

Last updated by the study team

2025-06-25

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 22
• Diagnosis of symptomatic benign bowel stricture with at least 2 previous dilations.
• Willing and able to complete protocol required follow up
• Willing and able to provide written informed consent
• Stricture length ≤ 5 cm

You may not qualify if…

• Female subjects who are pregnant or breastfeeding or plan to get pregnant in next 12 months
• Contraindication to endoscopy, anesthesia, or deep sedation.
• Suspicion of malignant bowel stricture NOTE: Biopsy should be taken for every stricture during the initial endoscopy, however endoscopic balloon dilation may proceed without awaiting results if suspicion for malignancy is low in the opinion of the investigator.
• Benign stricture due to extrinsic compression
• Stricture is not amenable to standard balloon dilation (e.g. severe angulation, unable to pass guidewire, etc.)
• Stricture complicated with abscess, fistula, perforation, leakage or varices
• Stricture segment has moderate to severe active inflammation at the time of treatment. Moderate to severe inflammation is defined as any one of; ulcers >0.5cm in diameter, ulcerated surface >10%, affected (inflamed) surface >50%, marked erythema, absent vascular pattern, significant friability, or erosions
• Multiple clinically significant strictures unable to be treated with a single balloon (i.e. total segment length must be ≤5cm) NOTE: Clinically significant strictures include those that are unable to be passed by the endoscope.
• Received steroid injections into target stricture in the last 8 weeks
• Stricture is not able to be dilated to ≥15mm in small bowel or ≥18mm in large bowel
• Diagnosis of metastatic cancer of any type that is not considered in remission or non-metastatic cancer that may require radiation treatment in the pelvic region (e.g. prostate cancer)
• Suspected perforation of gastrointestinal tract
• Active systemic infection
• Allergy to paclitaxel
• Severe coagulation disorders or current use of anticoagulant or antiplatelet medication that cannot be safely managed per relevant societal guidelines
• Chronic systemic steroid use (defined as greater than 10 mg/day) for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use
• Condition requiring treatment in urgent setting
• Life expectancy of less than 24 months
• Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, pharyngeal or cervical deformity, etc.
• Current participation in another pre-market drug or medical device clinical study unless in long term follow-up

Where it is running

• West Virginia University — Morgantown, West Virginia, United States (enrolling)
• University of California, Irvine — Irvine, California, United States (enrolling)
• Gastro Care Institute — Lancaster, California, United States (enrolling)
• Cedars Sinai — Los Angeles, California, United States (enrolling)
• San Diego Gastroenterology — San Diego, California, United States (enrolling)
• University of Colorado Anschutz — Aurora, Colorado, United States (enrolling)
• University of Florida — Gainesville, Florida, United States (enrolling)
• Borland-Groover — Jacksonville, Florida, United States (enrolling)
• Research Associates of South Florida — Miami, Florida, United States (enrolling)
• Honor Health — Scottsdale, Arizona, United States (enrolling)
• Orlando Health — Orlando, Florida, United States (enrolling)
• Orlando Health — Orlando, Florida, United States (enrolling)
• Gastroenterology Associates of Central Georgia, LLC — Macon, Georgia, United States (enrolling)
• Rush University — Chicago, Illinois, United States (enrolling)
• Kansas Gastroenterology, LLC — Wichita, Kansas, United States (enrolling)
• University of Louisville — Louisville, Kentucky, United States (enrolling)
• Tandem Clinical Research — Marrero, Louisiana, United States (enrolling)
• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
• Washington University — St Louis, Missouri, United States (enrolling)
• Rutgers University — Piscataway, New Jersey, United States (enrolling)
• New York Presbyterian Hospital- Columbia University Medical Center — New York, New York, United States (enrolling)
• Lenox Hill Hospital — New York, New York, United States (enrolling)
• University of North Carolina — Chapel Hill, North Carolina, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• Einstein Medical Center — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.